Biotech · Private company · Rockville, MD, US
Sanaria Inc.
Track this companyFree. Adds Sanaria Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- PfSPZ Challenge (7G8)Phase 1 · MalariaClinicalTrials.gov · fetched Nov 12, 2026
- PfSPZ Challenge (7G8) for CHMIPhase 1 · MalariaClinicalTrials.gov · fetched Nov 12, 2026
- PfSPZ VaccinePhase 1 · MalariaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Malaria CVD 36000; Gates INV090205PHASE1 · NOT_YET_RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07558122 · fetched Nov 12, 2026
- A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMIPHASE1 · TERMINATED · started Dec 6, 2022ClinicalTrials.gov NCT05604521 · fetched Nov 12, 2026
- Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve AdultsPHASE1 · COMPLETED · started Sep 27, 2021ClinicalTrials.gov NCT04966871 · fetched Nov 12, 2026
NIH awards10
- New cryovials with integral septum for cryopreservation of PfSPZ vaccine and PfSPZ challenge products.Fiscal year 2026 · $1MNIH RePORTER 1SB1AI195021-01 · fetched Nov 12, 2026
- Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoitesFiscal year 2026 · $1MNIH RePORTER 5U44AI124867-08 · fetched Nov 12, 2026
- A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stageFiscal year 2025 · $999.2KNIH RePORTER 5R44AI149927-05 · fetched Nov 12, 2026
- Progressing PfSPZ vaccines for malaria to licensure and commercializationFiscal year 2025 · $995.1KNIH RePORTER 5SB1AI174403-03 · fetched Nov 12, 2026
- Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccinesFiscal year 2025 · $945.5KNIH RePORTER 5U01AI155354-05 · fetched Nov 12, 2026
- Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.Fiscal year 2025 · $1MNIH RePORTER 5U01AI155356-05 · fetched Nov 12, 2026
- Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoitesFiscal year 2025 · $1MNIH RePORTER 5U44AI124867-07 · fetched Nov 12, 2026
- Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoitesFiscal year 2024 · $1MNIH RePORTER 2U44AI124867-06 · fetched Nov 12, 2026
- Conditional male lethal Anopheles stephensi line for the efficient manufacture of malaria vaccinesFiscal year 2024 · $300KNIH RePORTER 5R43AI174393-02 · fetched Nov 12, 2026
- Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitroFiscal year 2024 · $277.7KNIH RePORTER 5R43AI179439-02 · fetched Nov 12, 2026